Avectas, a cell engineering technology business and CCRM, with its subsidiary OmniaBio Inc., a CDMO that enables the development of cell therapies and associated technologies for clinical and commercial manufacture, have expanded their collaboration, to enable the development of gene-edited induced pluripotent stem cells (iPSCs) using Avectas' non-viral cell engineering platform, SOLUPORE.
Inceptor Bio has partnered with cell engineering technology company Avectas to improve CAR-T cell therapies’ development and manufacturing to treat solid tumours.
CAR-Ts have already changed the treatment landscape when it comes to blood cancers, but getting a cell therapy to market for solid tumors remains tantalizingly out of reach. Now, Inceptor Bio and cell engineering tech company Avectas are taking on the challenge.
GenScript USA Inc., the world's leading life-science research tools and services provider and Avectas, a cell engineering technology leader, are partnering to develop an improved non-viral cell therapy manufacturing process.
DUBLIN, April 16, 2020 /PRNewswire/ -- Avectas, an Irish based cell engineering technology business, has completed a significant new Series C equity funding of approximately $20 million, bringing the total equity invested in the business to date to $40 million. The funding was led by existing shareholders, including Seamus Mulligan, an experienced biopharmaceutical executive.
Avectas announced that the United States Patent and Trademark Office (USPTO) issued US Patent No. 10,612,042, which is central to the company's cell engineering technology, Solupore and expands Avectas' global Intellectual Property portfolio. This patent covers an approach for delivering a payload, such as a protein and/or nucleic acid, across a plasma membrane of a cell.